Fevipiprant

Drug Profile

Fevipiprant

Alternative Names: NVP-QAW-039; QAW-039; QAW39A; QAW39A2107

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Acetic acids; Anti-inflammatories; Antiallergics; Antiasthmatics; Pyridines; Pyrroles
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Allergic asthma; Asthma
  • Phase II Atopic dermatitis
  • No development reported Allergic rhinitis

Most Recent Events

  • 24 Jul 2017 Novartis plans a phase III trial for Asthma (NCT03226392)
  • 14 Jul 2017 Novartis Pharmaceuticals plans a phase III trial for Asthma (In adolescents, In adults, In the elderly, Adjunctive treatment) (NCT03215758)
  • 27 Mar 2017 Novartis plans a phase I trial in patients with Renal failure and in Healthy volunteers (NCT03087942)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top